PyroGenesis Canada (PYRGF) Competitors

$0.20 0.00 (0.00%)

As of 05/22/2026 03:00 PM Eastern

PYRGF vs. PLX, NGEN, IMUX, GALT, and HRTX

Should you buy PyroGenesis Canada stock or one of its competitors? MarketBeat compares PyroGenesis Canada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PyroGenesis Canada include Protalix BioTherapeutics (PLX), NervGen Pharma (NGEN), Immunic (IMUX), Galectin Therapeutics (GALT), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does PyroGenesis Canada compare to Protalix BioTherapeutics?

PyroGenesis Canada (NASDAQ:PYRGF) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

PyroGenesis Canada has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Protalix BioTherapeutics has a net margin of -21.03% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

In the previous week, Protalix BioTherapeutics had 4 more articles in the media than PyroGenesis Canada. MarketBeat recorded 5 mentions for Protalix BioTherapeutics and 1 mentions for PyroGenesis Canada. Protalix BioTherapeutics' average media sentiment score of 0.70 beat PyroGenesis Canada's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Protalix BioTherapeutics	Positive

Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 471.43%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Protalix BioTherapeutics has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.63	-$21.12M	-$0.04	N/A
Protalix BioTherapeutics	$76.38M	2.22	$8.31M	$0.18	11.67

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Protalix BioTherapeutics beats PyroGenesis Canada on 11 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

NervGen Pharma has higher earnings, but lower revenue than PyroGenesis Canada.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
PyroGenesis Canada	$9.14M	4.63	-$21.12M	-$0.04	N/A

In the previous week, NervGen Pharma had 11 more articles in the media than PyroGenesis Canada. MarketBeat recorded 12 mentions for NervGen Pharma and 1 mentions for PyroGenesis Canada. NervGen Pharma's average media sentiment score of 0.32 beat PyroGenesis Canada's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NervGen Pharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
PyroGenesis Canada	-115.14%	N/A	-60.81%

0.0% of PyroGenesis Canada shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NervGen Pharma currently has a consensus target price of $18.00, suggesting a potential upside of 765.38%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NervGen Pharma beats PyroGenesis Canada on 7 of the 10 factors compared between the two stocks.

How does PyroGenesis Canada compare to Immunic?

Immunic (NASDAQ:IMUX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 14.0% of Immunic shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunic presently has a consensus price target of $47.57, suggesting a potential upside of 264.53%. Given Immunic's stronger consensus rating and higher possible upside, research analysts clearly believe Immunic is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Immunic has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Immunic. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
PyroGenesis Canada	$9.14M	4.63	-$21.12M	-$0.04	N/A

In the previous week, Immunic had 12 more articles in the media than PyroGenesis Canada. MarketBeat recorded 13 mentions for Immunic and 1 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.00 beat Immunic's score of -0.52 indicating that PyroGenesis Canada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunic has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Summary

Immunic beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Galectin Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
PyroGenesis Canada	-115.14%	N/A	-60.81%

PyroGenesis Canada has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
PyroGenesis Canada	$9.14M	4.63	-$21.12M	-$0.04	N/A

Galectin Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galectin Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 340.00%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Galectin Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Galectin Therapeutics had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.00 beat Galectin Therapeutics' score of -1.00 indicating that PyroGenesis Canada is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Negative
PyroGenesis Canada	Neutral

Summary

Galectin Therapeutics beats PyroGenesis Canada on 8 of the 14 factors compared between the two stocks.

How does PyroGenesis Canada compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Heron Therapeutics presently has a consensus price target of $4.50, indicating a potential upside of 423.99%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Heron Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Heron Therapeutics and Heron Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 0.87 beat PyroGenesis Canada's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heron Therapeutics has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	1.05	-$20.19M	-$0.18	N/A
PyroGenesis Canada	$9.14M	4.63	-$21.12M	-$0.04	N/A

Heron Therapeutics has a net margin of -20.53% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Heron Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Heron Therapeutics beats PyroGenesis Canada on 10 of the 15 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceutical Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$42.32M	$927.43M	$9.38B	$12.34B
Dividend Yield	N/A	4.84%	3.56%	5.28%
P/E Ratio	-3.41	1.46	25.54	25.65
Price / Sales	4.63	119.63	4,734.44	86.28
Price / Cash	N/A	20.07	27.59	56.67
Price / Book	-20.46	7.59	5.04	7.14
Net Income	-$21.12M	-$3.64M	$792.97M	$335.98M
7 Day Performance	-35.84%	1.93%	1.17%	3.56%
1 Month Performance	-31.27%	76.78%	2.13%	2.54%
1 Year Performance	-37.39%	126.62%	32.13%	35.05%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.20 flat	N/A	-37.4%	$42.32M	$9.14M	N/A	90	Gap Up
PLX Protalix BioTherapeutics	3.3016 of 5 stars	$2.10 +3.4%	$12.00 +471.4%	+29.6%	$169.20M	$76.38M	N/A	200
NGEN NervGen Pharma	3.721 of 5 stars	$2.08 -43.5%	$18.00 +765.4%	N/A	$167.71M	N/A	N/A	N/A	Gap Up High Trading Volume
IMUX Immunic	3.7985 of 5 stars	$13.05 +6.1%	$47.57 +264.5%	+42.2%	$167.54M	N/A	N/A	70	Analyst Forecast Gap Down
GALT Galectin Therapeutics	1.7406 of 5 stars	$2.50 -0.8%	$11.00 +340.0%	+95.3%	$165.96M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. PLX, NGEN, IMUX, GALT, and HRTX

How does PyroGenesis Canada compare to Protalix BioTherapeutics?

Summary

How does PyroGenesis Canada compare to NervGen Pharma?

Summary

How does PyroGenesis Canada compare to Immunic?

Summary

How does PyroGenesis Canada compare to Galectin Therapeutics?

Summary

How does PyroGenesis Canada compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. PLX, NGEN, IMUX, GALT, and HRTX

How does PyroGenesis Canada compare to Protalix BioTherapeutics?

Which has more risk & volatility, PYRGF or PLX?

Is PYRGF or PLX more profitable?

Does the media prefer PYRGF or PLX?

Do analysts recommend PYRGF or PLX?

Which has better valuation & earnings, PYRGF or PLX?

Do insiders and institutionals have more ownership in PYRGF or PLX?

Summary

How does PyroGenesis Canada compare to NervGen Pharma?

Which has stronger earnings & valuation, NGEN or PYRGF?

Does the media prefer NGEN or PYRGF?

Is NGEN or PYRGF more profitable?

Do insiders and institutionals believe in NGEN or PYRGF?

Do analysts prefer NGEN or PYRGF?

Summary

How does PyroGenesis Canada compare to Immunic?

Do institutionals and insiders hold more shares of IMUX or PYRGF?

Do analysts rate IMUX or PYRGF?

Which has more volatility & risk, IMUX or PYRGF?

Which has better valuation & earnings, IMUX or PYRGF?

Does the media prefer IMUX or PYRGF?

Is IMUX or PYRGF more profitable?

Summary

How does PyroGenesis Canada compare to Galectin Therapeutics?

Is GALT or PYRGF more profitable?

Which has preferable valuation and earnings, GALT or PYRGF?

Which has more volatility & risk, GALT or PYRGF?

Do institutionals & insiders have more ownership in GALT or PYRGF?

Do analysts prefer GALT or PYRGF?

Does the media favor GALT or PYRGF?

Summary

How does PyroGenesis Canada compare to Heron Therapeutics?

Do analysts prefer HRTX or PYRGF?

Does the media favor HRTX or PYRGF?

Which has stronger valuation & earnings, HRTX or PYRGF?

Is HRTX or PYRGF more profitable?

Which has more risk and volatility, HRTX or PYRGF?

Do institutionals and insiders have more ownership in HRTX or PYRGF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools